ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TF/TOP1i Antibody-drug Conjugate XNW28012

Also written as “XNW28012” and “XNW28012 for injection”.

Its studies are mostly in Pancreatic Neoplasms, led by Evopoint Biosciences.

Drug pageAnti-TF/TOP1i Antibody-drug Conjugate XNW28012: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 21, 20263 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Evopoint Biosciences33 open or runningphase 3since Jul 21, 2026Dec 25, 2024Dec 31, 2026phase 2 · NCT06799637

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 25, 2024First study: phase 2 study in Pancreatic NeoplasmsFirst studyNCT06799637 · 350 planned · China
  2. Jul 6, 2026Phase 1 study in Pancreatic NeoplasmsNCT07707674 · 24 planned · United States
  3. Jul 21, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07823049 · 226 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Pancreatic NeoplasmsNCT06799637
  2. May 31, 2027Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07823049
  3. Apr 30, 2028Primary completion: phase 1 study in Pancreatic NeoplasmsNCT07707674

TargetBeta

F3 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against human tissue factor (TF; F3; coagulation factor III; thromboplastin; CD142) ”NCIt, by rule

Other programs on F3

ProgramCompanyFurthest phaseStudies
tisotumab vedotinrulePfizerphase 411
Anti-TF Antibody-drug Conjugate MRG004Arulelepu-biopharma-co-ltdphase 32
SHR-4375Jiangsu HengRui Medicinephase 22
Anti-TF/TOP1i Antibody-drug Conjugate XB371ruleExelixisphase 11
Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rulesutro-biopharma-incphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07823049Pancreatic Neoplasms · China3RecruitingMay 31, 2027226
NCT07707674Pancreatic Neoplasms · United States1Not yet recruitingApr 30, 202824
NCT06799637Pancreatic Neoplasms · China2RecruitingDec 31, 2026350

How it is read

Names in the registry

  • “XNW28012”, 2 entries
  • “XNW28012 for injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.